Show simple item record

dc.contributor.authorWellington, Jennifer
dc.contributor.authorMa, Andrew
dc.contributor.authorKottilil, Shyam
dc.contributor.authorRavichandran, Bharath
dc.contributor.authorHusson, Jennifer
dc.contributor.authorBruno, David
dc.contributor.authorWilson, Eleanor
dc.date.accessioned2021-09-30T14:11:11Z
dc.date.available2021-09-30T14:11:11Z
dc.date.issued2021-09-14
dc.identifier.urihttp://hdl.handle.net/10713/16747
dc.description.abstractLiver transplantation for hepatitis C virus (HCV)-related disease has the lowest five-year graft survival among all liver transplant recipients. Graft failure due to accelerated fibrosis from unrestrained HCV replication is common. Optimal timing of HCV treatment with direct-acting antiviral agents remains unknown. We compared HCV liver transplant recipients successfully treated for HCV before transplant to those treated within 1 year of transplant to determine if graft fibrosis, measured by Fib-4 scores, differs with timing of treatment. Fib-4 scores less than or equal to 1.45 defined minimal fibrosis and greater than 1.45 defined greater than minimal fibrosis. We identified 117 liver transplant recipients: 52 treated before transplantation and 65 treated within 1 year of transplantation. Overall, 34% of recipients had minimal fibrosis, and the likelihood of having minimal fibrosis following treatment and liver transplantation did not differ by timing of treatment. The odds ratio of having greater than minimal fibrosis was 0.65 (95% CI 0.30, 1.42) among those treated within 1 year after transplantation compared to those treated before transplantation (p-value 0.28). Importantly, nearly 2/3 of these patients had evidence of fibrosis progression one year after sustained virologic response, supporting recommendations for early antiviral-based treatment to prevent accumulation of HCV-related disease.en_US
dc.description.urihttps://doi.org/10.3390/v13091831en_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofVirusesen_US
dc.subjectgraft fibrosisen_US
dc.subjecthepatitis C Virusen_US
dc.subjectliver transplanten_US
dc.titleOutcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosisen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/v13091831
dc.identifier.pmid34578412
dc.source.volume13
dc.source.issue9
dc.source.countryUnited States
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record